Brun-Vézinet F - Search Results

1

Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vézinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group. Vray M, et al. Antivir Ther. 2003 Oct;8(5):427-34. doi: 10.1177/135965350300800510. Antivir Ther. 2003. PMID: 14640390 Clinical Trial.

2

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.

Le Moing V, Chêne G, Carrieri MP, Alioum A, Brun-Vézinet F, Piroth L, Cassuto JP, Moatti JP, Raffi F, Leport C; Aproco Study Group. Le Moing V, et al. AIDS. 2002 Jan 4;16(1):21-9. doi: 10.1097/00002030-200201040-00004. AIDS. 2002. PMID: 11741159 Clinical Trial.

3

Final analysis of the Trilège induction-maintenance trial: results at 18 months.

Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F. Flandre P, et al. AIDS. 2002 Mar 8;16(4):561-8. doi: 10.1097/00002030-200203080-00007. AIDS. 2002. PMID: 11872999 Clinical Trial.

4

Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F, Girard PM; Narval Trial Group. Meynard JL, et al. AIDS. 2002 Mar 29;16(5):727-36. doi: 10.1097/00002030-200203290-00008. AIDS. 2002. PMID: 11964529 Clinical Trial.

5

Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Flandre P, et al. Antivir Ther. 2002 Jun;7(2):113-21. Antivir Ther. 2002. PMID: 12212923 Clinical Trial.

6

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group. Masquelier B, et al. J Infect Dis. 2002 Nov 15;186(10):1503-7. doi: 10.1086/344358. Epub 2002 Oct 23. J Infect Dis. 2002. PMID: 12404170

7

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.

8

Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.

Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cécile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vézinet F. Calvez V, et al. Antivir Ther. 2002 Sep;7(3):211-8. Antivir Ther. 2002. PMID: 12487389

9

Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.

Flandre P, Descamps D, Joly V, Meiffrédy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vézinet F. Flandre P, et al. Antivir Ther. 2003 Feb;8(1):65-72. Antivir Ther. 2003. PMID: 12713066 Clinical Trial.

10

Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C; CNA3007 Study Group. Matheron S, et al. Antivir Ther. 2003 Apr;8(2):163-71. Antivir Ther. 2003. PMID: 12741629 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

358 results

Search Page

Filters